DNA Testing to Confirm Diagnosis of Pancreatic Lesions

KRAS mutations were identified in malignant, but not benign, solid pancreatic lesions.

Endoscopic ultrasound-guided fine-needle aspiration (EUS FNA) is the most common and successful technique used in evaluating solid pancreatic lesions for possible malignancy. But up to 10% to 15% of lesions sampled by EUS FNA may yield indeterminate pathology results.

Now, investigators in Denmark have conducted a single-center, retrospective study of patients with solid pancreatic lesions to determine if DNA testing would improve diagnostic accuracy in patients with inconclusive EUS FNA results without requiring them to undergo traditional follow-up procedures such as repeat EUS FNA, CT-guided biopsy, or, rarely, surgical biopsy.

DNA analysis of genes commonly mutated in cancer was performed on cytology specimens from 39 patients: 16 had sus…

Reviewing Author

Douglas G. Adler, MD, FACG, AGAF, FASGE

Disclosures

Consultant/Advisory BoardBSC; Merit; Olympus

Speaker’s BureauAbbVie

Editorial BoardsGastrointestinal Endoscopy

Douglas G. Adler, MD, FACG, AGAF, FASGE

Disclosures

Consultant/Advisory BoardBSC; Merit; Olympus

Speaker’s BureauAbbVie

Editorial BoardsGastrointestinal Endoscopy

DNA Testing to Confirm Diagnosis of Pancreatic Lesions

Topics

Reviewing Author